Author(s):
Seema B. Kharwade, Dipti B. Ruikar, Snehal S. Manekar, Nikita P. Shahane
Email(s):
seemabkharwade@gmail.com
DOI:
10.52711/0974-4150.2024.00042 
Address:
Seema B. Kharwade2*, Dipti B. Ruikar1, Snehal S. Manekar2, Nikita P. Shahane1
1P.R. Pote Patil College of Pharmacy, Amravati - 444604, MS, India.
2Dr. Rajendra Gode Institute of Pharmacy, Amravati - 444602, MS, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 4,
Year - 2024
ABSTRACT:
Drug repositioning encompassing the practise of finding new uses apart from the original therapeutic indication for old/available/existing drugs. The prominent repurposed drugs having two strategies of drug repurposing on-target as well as off-target some drug shows action drugs like Minoxidil (Rogaine) is one of the examples of an on-target profile shows action on hair loss and remain less potent antihypertensive. Metformin ameliorated to progression-free survival (PFS) and (NSCLC) OS in advanced, previously untreated non-small cell lung cancer. Metformin 500 mg/day was recently trailed in patients of lung adenocarcinoma along with erlotinib, afatinib or Gefitinib at standard recommended dose. In consequence it has been linked to the fetal abnormalities devastating teratogenic effects of thalidomide when taken in early pregnancy. Thalidomide also shows specific causes results to degradation of repressors in T-cells which play the role lead to activation with increased IL-2 secretion. This animate the immune system to fight cancer cells. Thus conclusion of repurposing medications in conjunction with other treatments has the potential action to enhance cancer patient outcomes with its indications might be quite useful. Drugs and disease-specific on targets and off targets have previously been screened for using in silico methods such as docking techniques, in vitro methods, and in vivo methods. But there are a number of technological and legal obstacles that require the development of fresh ideas.
Cite this article:
Seema B. Kharwade, Dipti B. Ruikar, Snehal S. Manekar, Nikita P. Shahane. Review of Drug Repositioning in Cancer Therapeutics. Asian Journal of Research in Chemistry. 2024; 17(4):237-2. doi: 10.52711/0974-4150.2024.00042
Cite(Electronic):
Seema B. Kharwade, Dipti B. Ruikar, Snehal S. Manekar, Nikita P. Shahane. Review of Drug Repositioning in Cancer Therapeutics. Asian Journal of Research in Chemistry. 2024; 17(4):237-2. doi: 10.52711/0974-4150.2024.00042 Available on: https://ajrconline.org/AbstractView.aspx?PID=2024-17-4-9
REFERENCES:
1. Rudrapal, M., Khairnar, S. J., Jadhav, A. G. Drug Repurposing (DR): An Emerging Approach in Drug Discovery. In: Badria, F. A., editor. Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications [Internet]. London: IntechOpen; 2020 [cited 2022 Apr 02]. Available from: https://www.intechopen.com/ chapters/72744 doi: 10.5772/intechopen.93193.
2. Ashburn, T., Thor, K. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3: 673–683.
3. Pushpakom S et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019; 18:41–58.
4. Jourdan JP, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview. J Pharm Pharmacol. 2020; 72(9): 1145-1151. doi:10.1111/jphp.13273.
5. March-Vila E et al. On the integration of in silico drug design methods for drug repurposing. Front Pharmacol. 2017; 8: 298–298.
6. Ferreira LG, Andricopulo AD. Drug repositioning approaches to parasitic diseases: A medicinal chemistry perspective. Drug Discovery Today. 2016; 21(10): 1699-1710.
7. Rudrapal, M., Khairnar, S. J., Jadhav, A. G. Drug Repurposing (DR): An Emerging Approach in Drug Discovery. In: Badria, F. A., editor. Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications [Internet]. London: IntechOpen; 2020 [cited 2022 Apr 03]. Available from: https://www.intechopen.com/ chapters/72744 doi: 10.5772/intechopen.93193.
8. Salim Ahmad, Khalid Raza, Translational bioinformatics methods for drug discovery and drug repurposing. Translational Bioinformatics in Healthcare and Medicine. 2021.
9. Thomas I, Gregg B. Metformin; a review of its history and future: from lilac to longevity. Pediatr Diabetes. 2017; 18: 10–6doi:10.1111/pedi.12473 Online First: Epub Date.
10. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 2010; 3: 1451–61. doi: 10.1158/1940-6207.CAPR-10-0157 [published Online First: Epub
11. Palazzolo G, Mollica H, Lusi V, et al. Modulating the distant spreading of patient-derived colorectal cancer cells via aspirin and metformin. Transl Oncol. 2020; 13: 100760. doi:10.1016/j.tranon.2020.100760 [published Online First: Epub Date.
12. Arrieta O, Barron F, Padilla MS, et al. Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019; e192553. doi: 10.1001/jamaoncol. 2019.2553
13. Pacal L, Kankova K. Metformin in oncology—how far is its repurposing as an anticancer Klin Onkol. 2020; 33: 107–13. doi: 10.14735/amko2020107
14. Lord SR, Cheng WC, Liu D, et al. Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer. Cell Metab. 2018; 28: 679, e4–88. doi: 10.1016/j.cmet.2018.08.021
15. Schein CH. Repurposing approved drugs on the pathway to novel therapies. Med Res Rev. 2020;40: 586–605. doi: 10.1002/med.21627
16. Mori T, Ito T, Liu S, et al. Structural basis of thalidomide enantiomer binding to cereblon. Sci Rep. 2018; 8: 1294. doi: 10.1038/s41598-018-19202-7.
17. Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide costimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol. 2014; 164: 811–21. doi: 10.1111/bjh.
18. Diaz-Carballo D., Acikelli A.H., Klein J., Jastrow H., Dammann P., Wyganowski T., Guemues C., Gustmann S., Bardenheuer W., Malak S., Tefett N.S., Khosrawipour V., Giger-Pabst U., Tannapfel A., Strumberg D. Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements. J. Exp. Clin. Cancer Res. 2015;34:81.
19. Stenvang J., Keinicke H., Nielsen S.L., Jandu H., Bartek J., Brünner N. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Philadelphia, PA. AACR; Philadelphia, PA: 2018. Repurposing disulfiram as a potential novel treatment of drug-resistant metastatic colorectal cancer [abstract] Abstract nr A143.
20. Skrott Z., Mistrik M., Andersen K.K., Friis S., Majera D., Gursky J., Ozdian T., Bartkova J., Turi Z., Moudry P., Kraus M., Michalova M., Vaclavkova J., Dzubak P., Vrobel I., Pouckova P., Sedlacek J., Miklovicova A., Kutt A., Li J., Mattova J., Driessen C., Dou Q.P., Olsen J., Hajduch M., Cvek B., Deshaies R.J., Bartek J. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 2017;552(7684):194–199.
21. Varnat F., Siegl-Cachedenier I., Malerba M., Gervaz P., Altaba A. Ruiz i. Loss of WNT-TCF addiction and enhancement of HH-GLI1 signalling define the metastatic transition of human colon carcinomas. EMBO Mol. Med. 2010; 2(11):440–457.
22. Falkowski M., Skogstad S., Shahzidi S., Smedsrod B., Sveinbjornsson B. The effect of cyclooxygenase inhibitor diclofenac on experimental murine colon carcinoma. Anticancer Res. 2003; 23(3B):2303–2308.
23. Koh S.L., Ager E.I., Costa P.L., Malcontenti-Wilson C., Muralidharan V., Christophi C. Blockade of the renin-angiotensin system inhibits growth of colorectal cancer liver metastases in the regenerating liver. Clin. Exp. Metastasis. 2014;31(4):395–405.
24. Luo Y., Ohmori H., Shimomoto T., Fujii K., Sasahira T., Chihara Y., Kuniyasu H. Anti-angiotensin and hypoglycemic treatments suppress liver metastasis of colon cancer cells. Pathobiology. 2011; 78(5):285–290.
25. Neo J.H., Malcontenti-Wilson C., Muralidharan V., Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J. Gastroenterol. Hepatol. 2007;22(4):577–584.
26. Jones M.R., Schrader K.A., Shen Y., Pleasance E., Ch'ng C., Dar N., Yip S., Renouf D.J., Schein J.E., Mungall A.J., Zhao Y., Moore R., Ma Y., Sheffield B.S., Ng T., Jones S.J., Marra M.A., Laskin J., Lim H.J. Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer. Ann. Oncol. 2016;27(5):801–806.
27. Miyajima A., Kosaka T., Asano T., Asano T., Seta K., Kawai T., Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 2002; 62(15):4176–4179.
28. Tonnesen H., Knigge U., Bulow S., Damm P., Fischerman K., Hesselfeldt P., Hjortrup A., Pedersen I.K., Pedersen V.M., Siemssen O.J., et al. Effect of cimetidine on survival after gastric cancer. Lancet. 1988; 2(8618):990–992.
29. Adams W.J., Morris D.L., Ross W.B., Lubowski D.Z., King D.W., Peters L. Cimetidine preserves non-specific immune function after colonic resection for cancer. Aust. N. Z. J. Surg. 1994; 64(12): 847–852.
30. Matsumoto S. Cimetidine and survival with colorectal cancer. Lancet. 1995; 346(8967):115.
31. Varnat F., Siegl-Cachedenier I., Malerba M., Gervaz P., Altaba A. Ruiz i. Loss of WNT-TCF addiction and enhancement of HH-GLI1 signalling define the metastatic transition of human colon carcinomas. EMBO Mol. Med. 2010; 2(11): 440–457.
32. Seth C., Altaba A. Ruiz I. Metastases and colon cancer tumor growth display divergent responses to modulation of canonical WNT signaling. PLoS One. 2016;11(3)
33. Duquet A., Melotti A., Mishra S., Malerba M., Seth C., Conod A., Altaba A. Ruiz i. A novel genome-wide in vivo screen for metastatic suppressors in human colon cancer identifies the positive WNT-TCF pathway modulators TMED3 and SOX12. EMBO Mol. Med. 2014; 6(7):882–901.
34. Tarpgaard L.S., Qvortrup C., Nygard S.B., Nielsen S.L., Andersen D.R., Jensen N.F., Stenvang J., Detlefsen S., Brunner N., Pfeiffer P. A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification. BMC Cancer. 2016;16:91.
35. Holdener E.E., Hansen H.H., Host H., Bruntsch U., Cavalli F., Renard J., Pinedo H.M., Rozencweig M. Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC) Investig. New Drugs. 1985; 3(1): 63–66.
36. Rokkas T., Portincasa P. Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis. European J. Int. Med. 2016; 33: 60–66.
37. Franciosi M., Lucisano G., Lapice E., Strippoli G.F., Pellegrini F., Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013; 8(8).